HIGH-SENSITIVITY CARDIAC TROPONIN T AND C-REACTIVE PROTEIN HAVE DIFFERENT PROGNOSTIC VALUES IN HAEMO- AND PERITONEAL DIALYSIS POPULATION: A COHORT STUDY

T CHEN1, 5, H HASSAN2, 7, M VU4, 5, P Rao1, 5, A MAKRIS3, 6

1The Westmead Institute for Medical Research, Westmead, NSW; 2Wollongong Hospital, Wollongong, NSW; 3Liverpool Hospital, Liverpool, NSW; 4Royal Prince Alfred Hospital, Camperdown, NSW; 5University of Sydney, Camperdown, NSW; 6University of New South Wales, Kensington, NSW; 7University of Wollongong, Wollongong, NSW

Aim: To evaluate the prognostic value of high sensitivity cardiac troponin T (hs-cTnT) and C-reactive protein (CRP) in stable haemodialysis (HD) and peritoneal dialysis (PD) patients.

Background: In dialysis population, clinical assessment based on traditional risk factors is inadequate in identifying patients at high risk of adverse outcome. Serum biomarkers can be a useful tool in risk stratification of this population.

Methods: A 3.5-year retrospective observational study of a cohort of 574 HD (n=347) and PD (n=227) patients. All-cause mortality and major adverse cardiovascular events (MACE) were assessed. SPSSv23 was used, P<0.05 was significant.

Results: No patient was lost to follow up. For HD patients, hs-cTnT remained relatively stable for the follow up period. For PD patients, hs-cTnT increased significantly every year (P<0.001).

High-sensitivity cardiac troponin T was an independent predictor of both outcomes in HD and PD patients. C-reactive protein was an independent predictor of both outcomes in PD patients only. Performing CRP in addition to hs-cTnT further improved risk prediction. The area under the receiver operating curves (AUC) for hs-cTnT (mortality AUC=0.706, MACE AUC=0.62) and traditional clinical parameters (mortality AUC=0.703, MACE AUC=0.634) were similar and they were larger than CRP (mortality AUC=0.591, MACE AUC=0.523). Adding hs-cTnT to traditional clinical parameters significantly increased its AUC (P=0.018).

Conclusions:

  1. Both hs-cTnT and CRP have a useful role in predicting adverse outcomes in dialysis patients at 3.5 years. Their prognostic performance is different in HD and PD patients.
  2. Adding hs-cTnT to traditional clinical parameters significantly improves the its prognostic performance.
  3. The frequency of hs-cTnT measurement should be at least yearly for PD. For HD patients, a less frequent measurement may be acceptable.

About ANZSN

The ASM is hosted by Australian and New Zealand Society of Nephrology.

The aims of the Society are to promote and support the study of the kidney and urinary tract in health and disease, and to ensure the highest professional standards for the practice of nephrology in Australia and New Zealand.

Conference Managers

Please contact the team at Conference Design with any questions regarding the Annual Scientific Meeting

/wp-content/uploads/2017/08/Conference-Design-400×400.png

© 2015 - 2016 Conference Design Pty Ltd